“From Discovery of a New Drug to a Digital Center of Excellence for Chronic Itch”

Based on the original discovery in the Kim Lab at WashU that Janus kinase (JAK) signaling in neurons critically mediates itch, Dr. Brian Kim and Duke Leahey co-founded Nuogen Pharma to develop JAK inhibitors for itch by way of a novel route of delivery. Currently, there are no FDA-approved medications specifically for chronic itch. Beyond treatments, recognizing the highly unmet need for patients in terms of diagnosis, education, management, and access, Dr. Kim and Duke decided to start an online digital center of excellence called SootheRx. This platform aims to revolutionize and innovate the delivery of care itself while simultaneously bringing new treatments to patients with chronic itch in the most effective and efficient manner possible.

For more information visit the ICTS Precision Medicine website.

The Institute of Clinical and Translational Sciences (ICTS) Precision Medicine team invites you to an on-going collaboration with Venture Café. These sessions will be hosted on the third Thursday of every month.